The European Commission (EC) has approved AstraZeneca’s Bydureon BCise, a new weekly formulation of established GLP-1 diabetes drug with the added benefit of glucose reduction, better weight loss ...
AstraZeneca has had a setback to its ambitions in diabetes, after Bydureon failed to show cardiovascular benefits to patients. The FDA now obliges companies with diabetes products to conduct large ...
We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Melanie Pinola If you’ve ever had a pen mysteriously wander away from your ...
The S Pen has been one of the standout features on Samsung flagships for many years. First integrated with the Note line, the S Pen is now a core part of the Galaxy S Ultra models, certain foldables, ...
Myers' upcoming $30B patent cliff as the Growth portfolio lost significant potential. Read why BMY stock is downgraded to Hold.
Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...
Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results